Dimerix (ASX:DXB) has announced a new patent family application for its lead investigative candidate DMX-700 for the treatment of Chronic Obstructive Pulmonary Disease.
The company said the application follows the recently announced 80 per cent reduction versus control in induced lung injury in mice.
It said the new provisional patent application (Australian number 2022902171) is titled ‘Dosage regimen for the treatment of COPD’. It has a priority date of 2 August 2022 and if granted would expire post-2043.
“This new patent application bolsters the existing DMX-700 global patent application PCT number PCT/AU2020/050987, which was filed in September 2020. It is anticipated that DMX-700 will be protected by Composition of Matter patents, Formulation patents and Method of Use patents, providing a strong competitive position,” said the company.
“This is clearly a very exciting and busy time for Dimerix at the moment, with multiple activities that could each add significant value to the company. Our flagship Phase 3 program in FSGS is progressing well, and our second pipeline candidate, DMX-700 has demonstrated some very encouraging pre-clinical data.
“The DMX-700 study identified some very surprising outcomes, which we believe further strengthens our IP position moving forward. We look forward to finalising the clinical study design and anticipate initiating this study in the first half of 2023,” said Dimerix CEO and managing director Dr Nina Webster.
